SOHO 2023 | BTK degraders for treatment of CLL and B-cell lymphoma
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses the mechanism of action of BTK degraders, highlighting the advantages of this new class of drug in comparison to small molecule inhibitors. Dr Patel also comments on the study of BTK degraders in patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas, who were previously exposed to covalent and non-covalent BTK inhibitors. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
BTK degraders are a really interesting class of new therapies that are being studied also broadly in B-cell malignancies. They work by targeting the BTK protein to be destroyed by a pathway called the ubiquitin ligase proteasome pathway. The potential advantage of a degrader as opposed to a small molecule inhibitor, is where small molecules may be rendered insensitive by point mutations in the protein, they may not be able to bind to their target...
BTK degraders are a really interesting class of new therapies that are being studied also broadly in B-cell malignancies. They work by targeting the BTK protein to be destroyed by a pathway called the ubiquitin ligase proteasome pathway. The potential advantage of a degrader as opposed to a small molecule inhibitor, is where small molecules may be rendered insensitive by point mutations in the protein, they may not be able to bind to their target. With a degrader, we might be able to overcome that resistance by actually destroying the entire protein. We’re then not so dependent on the binding of that drug for its mechanism of action. These therapies are being studied in patients who have been exposed to both covalent BTK inhibitors and now even patients who have progressed on non-covalent BTK inhibitors with initial signal of activity in those settings.
Read more...
